The aim: To research differences of interleukin (IL)-17 and IL-23 serum levels in patients with Alzheimer’s disease, vascular dementia and mild cognitive impairment. Material and methods: Serum levels of IL-17 and IL-23 were measure by ELISA for 15 patients with Alzheimer’s disease, 14 with vascular dementia, 30 with mild cognitive impairment and 30 control individuals without cognitive impairment. Results: Serum concentrations of IL-17 were significantly higher in Alzheimer’s disease patients (P=0.0023) than control, in vascular dementia no significant differences(P=0.4154). Level of IL-23 was significantly higher than control in Alzheimer’s disease patients (P=0.0170) and vascular dementia (P=0.0002), but in Alzheimer’s disease it was in 12.5 time higher. In total mild cognitive impairment patients no significant differences in interleukin concentration with control, but significant differences observed for amnestic form in IL-17 (P=0.0436) and IL-23 (P=0.0019). Conclusions: IL-17 and IL-23 level significant higher in Alzheimer’s disease patients compared with control and vascular dementia. From mild cognitive impairment levels of detectable interleukins was higher in amnestic form that may be early marker of progression in Alzheimer’s disease.
Alzheimer's disease (AD) is a degenerative disease that leads to dementia symptoms [1, 2]. Histopathological signs of AD are amyloid plaques in the brain, mainly consisting of fibrillary forms of amyloid β-peptide-40 (Aβ-40) and amyloid β-peptide-42 (Aβ-42). Neutrophils are the main targets for IL-17 in the central nervous system (CNS) that promote inflammation and damage to CNS tissues, and may play an important role in the development of AD pathology. Interleukin 23 (IL‑23) synergizes with IL-6, IL-1 and is involved in the differentiation of Th17 cells in a pro-inflammatory context. The aim of the study was to analyze the relationship between interleukin levels of IL-17, IL-23 and neurocognitive scales in patients with AD, vascular dementia (VD) and mild cognitive disorder (MCD). The study involved 89 patients, of which 59 patients had cognitive impairment (32 men and 27 women, mean age 66.8±8.4 years); among them, 29 had major neurocognitive impairment (NCD), including 15 patients with AD, 14 – with VD, 30 patients – with MCD and 30 people in the control group had no cognitive deficit. All patients were tested with comprehensive neuropsychological examination using the following tests and scales: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Frontal Assessment Battery (FAB), Alzheimer Disease Assessment Scale-cognitive (ADAScog). Serum levels of cytokines of IL-17 and IL-23 were assayed using sandwich ELISA on «Chem Well 2900» immunoanalyzer (Awareness Technology, USA). Test systems using Bender Medsystems, Australia (IL-17 and IL-23) were used in accordance with the manufactures instructions. Levels of detectable interleukins (IL-17 and IL-23) were significantly higher in patients with AD vs. patients with VD and MCD. The correlations between the two cytokines and the MMSE scales, MoCA, ADAS-cog and FAB were examined. Our results showed a significant positive correlation between the serum concentration of IL-23 and neurocognitive scales in all patients with AD. The most relevant correlations in the AD group were linked with the scales: ADAS-cog (r = 0.760; р = 0.001), namely with the sections «tasks for repeating words» (r = 0.775; p ˂ 0.001), «constructive praxis» (r = 0.651; p = 0.010), «orientation» (r = 0.684; p = 0.01), as well as «word recognition tasks» (r = 0.616; p = 0.020); and with MoCA scale (r = −0.592; p = 0.020), namely with the section «delayed recall» (r = −0.641; p = 0.010). A significant positive correlation was established between IL-23 and individual sections of the ADAS-cog scale in patients with MCD (r = 0.423; p = 0.020), namely with «word recognition tasks» (r = 0.466; p = 0.030), «understanding» (r = 0.306; p = 0.059) as well as «strike out numbers» (r = 0.301; p = 0.061). A weak positive correlation was found between the serum concentration of IL-23 and ADAS-cog scores in patients with VD (r = 0.497; p = 0.045). Moderate positive correlation was observed for IL-23 with «concentration and distraction» (r = 0.558; p = 0.040). An inverse correlation was established between the serum levels of IL-23 and MoCA scores in patients with VD (r = −0.510; р = 0.060), especially with «language» (r = −0.538; p = 0.047) and «executive functioning» (r = −0.485; p = 0.079). However, no other significant correlations were found between the serum concentration of IL-17 and neurocognitive domains in patients with MCD and VD. Correlation analysis confirmed the relationship between the severity of cognitive impairment and the level of proinflammatory markers, suggesting that inflammation can lead to cognitive decline in AD patients. The results of the study indicated that IL-23 may have a more complex relationship with the progression of this disease which gives reason to consider IL-23 as a marker of inflammatory activity. Levels of detectable proinflammatory cytokines (IL-17 and IL-23) were significantly higher in patients with AD vs. patients with VD and MCD. Such more pronounced changes in the production of interleukin 23 in patients with AD may indicate the activity of the inflammatory process. The level of IL-23 in all examined patients with Alzheimer's disease had high correlations with indicators of neurocognitive scales, which indicated its important role in the pathogenesis of this disease. There were no other significant correlations between the serum concentration of IL-17 and neurocognitive domains in patients with MCD and VD.
Clinical neurocognitive methods are central to the identification of cognitive disorders. The article discusses the neurocognitive convergence and differences between Alzheimer's disease and vascular dementia. Aim of the study was to research differences of cognitive profiles in patients with Alzheimer's disease and vascular dementia.
Cognitive impairment in patients with major cognitive impairment is often accompanied by behavioral and mental violations (BMV). BMV is common in both patients with major neurodegenerative cognitive impairment due to Alzheimer’s disease (MNDCI) and patients with major vascular cognitive impairment (MVCI). As cognitive impairment progresses, there is a gradual loss of basic activities in daily life such as feeding, dressing, bathing and movement, which are necessary for independent functioning. The article considers behavioral and psychoneurological symptoms and evaluates the functional activity in everyday life in patients with major cognitive impairment of various etiologies. To make a comparative characterization of the prevalence of behavioral and psychoneurologicall symptoms and to assess the functional activity in everyday life in patients with major cognitive impairment of various etiologies. Psychoneurological symptoms in patients with major cognitive impairment were quite heterogeneous and differed in structure and frequency of manifestations. Behavioral disorders in the vast majority of cases were significantly more common in patients MVCI (73.3 %) than MNDCI (36.7 %), p = 0.0040. Affective disorders (depressive) were also observed more often in patients with MVCI (67.8 %) than with MNDCI (38.2 %), p = 0.0370. When assessing the prevalence of psychoneurological symptoms on the NPI scale in patients with MVCI with the same severity, more pronounced depression/dysphoria (p = 0.0281), apathy/indifference (p = 0.0412) were noted. In patients with MNDCI, sleep and nocturnal behavioral disorders (p = 0.0389), irritability/mood lability (p = 0.0480). When assessing activity in daily life on the BADLS scale, no significant differences were observed in the total number of points in patients with MNDCI and MVCI (14,6 ± 3,35), (19,0 ± 4,06), р = 0,3961. However, an important feature of the comparative characteristics of the functional status in MNDCI and MVCI in mild disease severity were the presence of more significant and probable differences in subtests: «ability to shop» (p = 0.0047), «time orientation» (p = 0.0242), «cooking» p = 0.0335), «use of transport» (p = 0.0439). In patients with MVCI moderate degree by subtests: «dressing» (p = 0.0035), «time orientation» (p = 0.0421), «walking» (p = 0.0473). Thus, according to the results of the study, patients with MVCI had more serious behavioral, psychoneurological symptoms and functional disorders than patients with MNDCI.
IntroductionAlzheimer’s disease (AD) is a degenerative brain disease and the most common cause of dementia. Evidence suggests that various cytokines, including interleukins (IL) IL-6, IL-10, IL-12 are actively involved in the pathogenesis of AD. The role of IL-17 and IL-23 is less clear.ObjectivesTo investigate the correlations between IL-17, IL-23, and neurocognitive scales in patients with Alzheimer’s disease.MethodsThe study included 45 patients: 15 patients with Alzheimer’s disease and 30 patients without cognitive deficit (control group). Clinical and psychometrical methods were used: Mini Mental State Examination (MMSE) scale; Montreal Cognitive Assessment (MoCA), Frontal Assessment Battery (FAB), Alzheimer Disease Assessment Scale-cognitive (ADAS ̶ cog). Serum levels of cytokines of IL-17 and IL-23 were analyzed by sandwich ELISA on “Chem Well 2900” immunoanalyzer (Awareness Technology, USA).ResultsA significantly positive correlation was observed between IL-17 and IL-23 for all AD patients (r =0.723, p=0.002). A significant inverse correlation was observed between serum concentration of IL-17 and MoCA score (r=˗1.0, р≤.0001) and IL-23 and MMSE score (r=˗0.553, р=0.032) in all AD patients. However, no other significant correlations were found between IL-17 and the scores MMSE, FAB, ADAS ̶ cog and between IL-23 and the scores MoCA, FAB and ADAS ̶ cog.ConclusionsProinflammatory cytokines (such as IL-17 and IL-23) have been associated with cognitive impairment. However, the complicated relationships of the two cytokines with the pathogenesis of AD need to be further investigated in the future.DisclosureNo significant relationships.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.